We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+9.8%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
-$33.5M
Cap. Flow
+$39.4M
Cap. Flow %
2.34%
Top 10 Hldgs %
67.67%
Holding
67
New
9
Increased
19
Reduced
9
Closed
16

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$47.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$44.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$34.3M
4
SNY icon
Sanofi
SNY
+$30.8M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$19.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$29.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18.1M
3
IRTC icon
iRhythm Holdings
IRTC
+$17.6M
4
UTHR icon
United Therapeutics
UTHR
+$14.7M
5
LLY icon
Eli Lilly
LLY
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$407M 24.17%
2,073,124
– –
NTRA icon
2
Natera
NTRA
$37.5B
$125M 7.39%
3,100,560
-2,400
-0.1% -$98.9K
JBIO
3
Jade Biosciences
JBIO
$1.22B
$110M 6.54%
107,391
– –
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$108M 6.38%
880,800
+380,976
+76% +$44.2M
SNY icon
5
Sanofi
SNY
$104B
$95.2M 5.65%
1,965,475
+700,929
+55% +$30.8M
CINC
6
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$74.6M 4.43%
6,073,949
-6,000
-0.1% -$143K
MRK icon
7
Merck
MRK
$324B
$66.9M 3.97%
603,356
+19,888
+3% +$2.03M
VERA icon
8
Vera Therapeutics
VERA
$2.54B
$61.6M 3.65%
3,181,442
– –
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$47M 2.79%
+413,173
New +$34.3M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$121B
$45.3M 2.69%
+156,989
New +$47.8M
AZN icon
11
AstraZeneca
AZN
$263B
$41.6M 2.47%
306,837
-44,102
-13% -$5.53M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.5B
$40.8M 2.42%
394,643
+99,893
+34% +$9.38M
RETA
13
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$37.7M 2.24%
992,029
+173,653
+21% +$5.98M
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.66B
$32.1M 1.91%
247,955
+106,515
+75% +$12.3M
CTIC
15
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$27.7M 1.64%
4,606,527
+994,151
+28% +$5.43M
INBX
16
DELISTED
Inhibrx, Inc. Common Stock
INBX
$27.4M 1.62%
1,110,183
+660,006
+147% +$19.4M
UTHR icon
17
United Therapeutics
UTHR
$26.3B
$24.8M 1.47%
89,207
-58,357
-40% -$14.7M
ALNY icon
18
CALL
Alnylam Pharmaceuticals
ALNY
$36.3B
$23.8M 1.41%
+100,000
New +$21.3M
CYTK icon
19
Cytokinetics
CYTK
$11B
$23.3M 1.38%
508,930
+188,208
+59% +$8.1M
KDNY
20
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$21.1M 1.25%
806,459
+518,558
+180% +$11.5M
ZNTL icon
21
Zentalis Pharmaceuticals
ZNTL
$308M
$20.2M 1.2%
1,004,045
+420,688
+72% +$9.05M
RXDX
22
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$19.4M 1.15%
176,545
+36,771
+26% +$2.38M
SNDX icon
23
Syndax Pharmaceuticals
SNDX
$1.84B
$17.9M 1.06%
703,074
+178,072
+34% +$4.15M
ALGN icon
24
Align Technology
ALGN
$12B
$17.5M 1.04%
+83,100
New +$16.6M
IMTX icon
25
Immatics
IMTX
$1.24B
$17.4M 1.03%
2,000,776
+1,468,260
+276% +$15.2M
1
2 3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2022 Portfolio in Review

As of Q4 2022, Sofinnova Investments held 67 positions worth $1.69B, down 1.9% from $1.72B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sofinnova Investments's Q4 2022 filing shows 9 new, 19 increased, 9 reduced and 16 closed positions. Its largest new stake was Vertex Pharmaceuticals: 156,989 shares worth $45.3M. The largest sale was Gilead Sciences, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 91% a quarter earlier.

  • Sofinnova Investments's largest Q4 2022 buy was Vertex Pharmaceuticals: 156,989 shares worth $45.3M.
  • Sofinnova Investments added most to Ascendis Pharma A/S in Q4 2022, an estimated $44.2M increase.
  • Sofinnova Investments's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $14.7M.
  • Sofinnova Investments fully exited Gilead Sciences in Q4 2022, selling an estimated $29.8M.
  • Sofinnova Investments's ten largest holdings make up 68% of its $1.69B portfolio in Q4 2022.
  • Sofinnova Investments opened 9 new positions and closed 16 in Q4 2022.
  • Sofinnova Investments's portfolio value fell 1.9% quarter-over-quarter to $1.69B.

Based on Sofinnova Investments's 13F filing for Q4 2022, filed 14 Feb 2023.